Xenon Pharmaceuticals Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; this is an annual report, not a standalone fourth-quarter filing. Amounts are in U.S. dollars unless otherwise stated.
Business context
Xenon is a clinical-stage biopharmaceutical company developing neurology-focused therapies, principally for epilepsy. It had no marketed proprietary products and relied on collaboration, licensing, equity and debt financing. Key programs included XEN1101, in Phase 2b testing for focal epilepsy; XEN496, a pediatric ezogabine formulation planned for Phase 3 development in KCNQ2-DEE; and XEN007, being studied in an investigator-led Phase 2 trial for childhood absence epilepsy. Partnered programs included NBI-921352 with Neurocrine and FX301 with Flexion.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $6.8 million | None |
| Research and development expense | $38.8 million | $23.6 million |
| General and administrative expense | $10.8 million | $8.4 million |
| Net loss | $41.6 million | $34.5 million |
| Basic and diluted loss per common share | $1.54 | $1.63 |
| Cash and cash equivalents plus marketable securities, at year-end | $141.4 million | $119.3 million |
- Revenue came primarily from Flexion ($3.5 million, including a $3.0 million upfront payment and a $0.5 million milestone) and Neurocrine ($3.3 million recognized in 2019). No significant product-sale or royalty revenue was reported.
- Operating loss was $42.8 million. No product margins are meaningful at this development stage. R&D spending increased $15.2 million, mainly on clinical candidates, especially XEN1101 and XEN901/NBI-921352.
- Net cash used in operating activities was $4.6 million, compared with $34.7 million in 2018. The 2019 figure benefited substantially from collaboration cash receipts and a $30.5 million increase in deferred revenue; it should not be read as the company’s underlying operating cash burn.
- Net cash used in investing was $66.3 million, largely reflecting purchases of marketable securities; financing provided $27.5 million. Year-end total assets were $147.7 million and shareholders’ equity was $92.0 million.
- Term-loan principal was $15.5 million, with $4.65 million classified as current. The loan bears interest at prime plus 0.5%, is secured by substantially all assets other than intellectual property, and has restrictive covenants. Scheduled principal repayment began after March 31, 2020; maturity is September 2022. The company reported covenant compliance at year-end.
- 2019 revenue growth and the smaller operating cash outflow did not prevent a larger net loss: higher R&D and G&A spending outweighed collaboration revenue, while 2018 included a $4.4 million Teva termination gain.
Material developments, outlook and risks
- In December 2019, Xenon licensed XEN901 (renamed NBI-921352), other sodium-channel candidates and related research to Neurocrine. The agreement included $50 million upfront consideration—$30 million cash and a $20 million equity investment—and potential development, regulatory and sales milestones and royalties. Neurocrine anticipated filing an IND in mid-2020 and starting a Phase 2 study in SCN8A-DEE in the second half of 2020; these were plans, not achieved results.
- In September 2019, Flexion acquired global rights to XEN402/FX301 for $3 million upfront, with additional contingent milestones and royalties. Flexion indicated it expected to start clinical trials in 2021.
- Management anticipated XEN1101 Phase 2b X-TOLE top-line results in the second half of 2020, depending on enrollment. XEN496’s adult PK study was underway, with results expected in Q1 2020, FDA feedback on the Phase 3 design expected early Q2 2020, and a Phase 3 start anticipated in 2020. XEN007 proof-of-concept results were expected in 2020.
- Management expected significant expenses and operating losses to continue for at least the next 12–24 months and did not expect sustained profitability for the foreseeable future. It stated that year-end cash, cash equivalents and marketable securities were expected to fund operations and capital needs for at least 12 months, while also warning that resources would not suffice to complete clinical development and prepare for commercialization of a candidate.
- After year-end, Xenon raised $64.9 million net of underwriting discounts and commissions, before offering expenses, through a January–February 2020 public offering. It also sold shares through its ATM program, reporting $48.8 million net proceeds as of January 14, 2020. These subsequent financings increased liquidity but diluted shareholders.
- Principal risks include clinical-trial failure or delay, enrollment and regulatory uncertainty, reliance on collaborators and third-party manufacturers, need for future capital, potential dilution, intellectual-property exposure, and the possibility that orphan-market size, pricing or reimbursement will not support commercial returns. The filing also identified potential disruption from COVID-19 to global supply chains and clinical sites.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting as of year-end. Management also concluded disclosure controls and internal controls were effective.
Most important facts for investors to verify
- Whether XEN1101’s Phase 2b trial met its primary endpoint and whether the results supported further development.
- Whether XEN496’s pediatric formulation, FDA-agreed trial design and planned Phase 3 program progressed as anticipated.
- Neurocrine’s actual IND filing and development progress for NBI-921352, and whether contingent milestone payments were achieved.
- Updated cash runway, operating cash use, debt repayments and any further financing or share dilution; distinguish reported operating cash flow from cash use before collaboration receipts.
- Whether Flexion advanced FX301 and whether any milestone or royalty conditions were met.
- Any material changes to clinical timelines, regulatory status, trial safety, manufacturing, intellectual-property rights or the company’s stated liquidity outlook.